Dexamethasone increases blood glucose levels in diabetics

Article

The use of dexamethasone eye drops following cataract surgery has a greater effect on the blood glucose profile of diabetic subjects than in diabetic subjects treated with diclofenac.

The use of dexamethasone eye drops following cataract surgery has a greater effect on the blood glucose profile of diabetic subjects than in diabetic subjects treated with diclofenac, according to the results of a study published in the September issue of Current Eye Research.

Irit Bahar and colleagues from the Sackler Faculty of Medicine at Tel Aviv University, Israel, randomized 285 patients undergoing cataract surgery to receive treatment with topical dexamethasone or diclofenac for one month. Capillary blood samples were collected prior to surgery, immediately following surgery and one week and one month postoperatively.

The researchers noted a significant increase in blood glucose levels in the diabetic dexamethasone group; 170±55.5 mg/dl preoperatively to 229±76.8 mg-dl one month postoperatively. These levels were significantly higher than those found in the diabetic patients treated with diclofenac drops (p=0.038).

It was the conclusion of the authors that dexamethasone eye drops can induce higher levels of blood glucose in diabetic patients than in those treated with diclofenac.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.